Accelerated immunotherapy schedules (Q38111236)

29 August 2017

Accelerated immunotherapy schedules (English)

1 reference

29 August 2017

1 reference

Christopher W Calabria

series ordinal

1

1 reference

29 August 2017

1 August 2013

1 reference

Current Allergy and Asthma Reports

29 August 2017

1 reference

29 August 2017

13

1 reference

29 August 2017

4

1 reference

29 August 2017

389-398

1 reference

https://scigraph.springernature.com/pub.10.1007/s11882-013-0356-x

29 August 2017

0 references

cites work

Safety of accelerated schedules of subcutaneous allergen immunotherapy with house dust mite extract in patients with atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Early gene expression changes with rush immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Enhancement of the frequency and function of IL-10-secreting type I T regulatory cells after 1 year of cluster allergen-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Accelerated immunotherapy schedules: review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Systemic reactions from allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Clustered schedules in allergen-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Safety of rush immunotherapy to multiple aeroallergens in an adult population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Specific ultrarush desensitization in Hymenoptera venom-allergic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Imported fire ant hypersensitivity: a 1-day rush immunotherapy schedule without premedication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Premedication with montelukast reduces local reactions of allergen immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Immunotherapy with cat- and dog-dander extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-013-0356-X

Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy

21 January 2018

1 reference

12 December 2020

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma

1 reference

12 December 2020

Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment

1 reference

12 December 2020

Hymenoptera Venom Immunotherapy: Tolerance and Efficacy of an Ultrarush Protocol versus a Rush and a Slow Conventional Protocol

1 reference

12 December 2020

Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis

1 reference

12 December 2020

Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study

1 reference

12 December 2020

Accelerated immunotherapy schedules and premedication

1 reference

12 December 2020

Safety of specific immunotherapy using a depigmented and polymerised extract of Dermatophagoides pteronyssinus in children under five years of age

1 reference

12 December 2020

Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus

1 reference

12 December 2020

Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study

1 reference

12 December 2020

Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations

1 reference

12 December 2020

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract

1 reference

12 December 2020

Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study

1 reference

12 December 2020

Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one.

1 reference

12 December 2020

Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts

1 reference

12 December 2020

Rush allergen subcutaneous immunotherapy administered with infusion pump

1 reference

12 December 2020

Evaluation of paediatric tolerance to an extract of Alternaria alternata under two treatment regimes. A multicentre study

1 reference

12 December 2020

Rush immunotherapy: experience with a one-day schedule

1 reference

12 December 2020

Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts

1 reference

12 December 2020

Total tryptase levels indicate risk for systemic reactions to rush immunotherapy and mast cell activation

1 reference

12 December 2020

Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis

1 reference

12 December 2020

Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type I T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children

1 reference

12 December 2020

Incidence of systemic reactions during rush immunotherapy

1 reference

12 December 2020

The adhesion molecule ICAM-1 is overexpressed in patients with Hymenoptera venom allergy and decreases after ultrarush venom immunotherapy

1 reference

12 December 2020

Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.

1 reference

12 December 2020

Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy

1 reference

12 December 2020

Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment

1 reference

12 December 2020

A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy

1 reference

12 December 2020

Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects

1 reference

12 December 2020

Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment

1 reference

12 December 2020

Short-term venom immunotherapy induces desensitization of FcεRI-mediated basophil response.

1 reference

12 December 2020

Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Comparison between rush immunotherapy with a standardized allergen and an alum adjuved pyridine extracted material in grass pollen allergy.

1 reference

12 December 2020

Systemic reactions occurring during immunotherapy with standardized pollen extracts

1 reference

12 December 2020

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

1 reference

12 December 2020

Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis.

1 reference

12 December 2020

Laboratory markers of mast cell and basophil activation in monitoring rush immunotherapy in bee venom-allergic children

1 reference

12 December 2020

Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract

1 reference

12 December 2020

Rush immunotherapy with a standardized Bermuda grass pollen extract

1 reference

12 December 2020

10.1007/S11882-013-0356-X

Identifiers

DOI

1 reference

PubMed ID

23728613

Dimensions Publication ID

29 August 2017

1039823432

0 references

Fatcat ID

release_accyzpkbfredzm6pf3z6glirhq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/accyzpkbfredzm6pf3z6glirhq

24 November 2022

mapped directly with Wikidata item

PubMed ID

23728613

1 reference

PubMed ID

23728613